Worldwide Market Reports

Key Insights of Global Veterinary Pain Management Drugs Market Covering Prime Factors and Competitive Outlook Till 2027

Rising collective efforts by key players to improve their product portfolio and to ensure high-quality standards are projected to boost the regional demand. For instance, in May 2017, Norbrook launched chewable Carprieve tablets for dogs in a probe to expand its product portfolio.In November 2018, Elanco collaborated with Novozymes A/S in a probe to improve its animal health products.


Seattle, WA -- (SBWIRE) -- 11/29/2019 -- Veterinary Pain Management Drugs Report by Material, Application, and Geography - Global Forecast to 2027 is a professional and comprehensive research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, United Kingdom, Japan, South Korea and China).

To Get Free Sample of This Research Report:

The report firstly introduced the Veterinary Pain Management Drugs basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analysed the world's main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

Increasing incidence of pet obesity is further fuelling the veterinary pain management market. According to the Association for Pet Obesity Prevention (APOP) in 2017, 56% dogs and 59% cats were recorded as obese in U.S. Obesity increases the risk of joint diseases, diabetes mellitus, cancer and other chronic conditions. Furthermore, according to kingsbrookvets, in 2017, 20% of all pet dogs in U.S. had osteoarthritis regardless of their age. Obesity also increases the risk of cancer in canines.

Rise in initiatives by government organisations to promote animal health globally, is expected to contribute to the market growth. For instance, in 2016 the European government invested USD 4.7 million in animal healthcare expenditure according to a report by the European External Action Service (EEAS). In January 2016, central state government of India raised the import duty on veterinary products from 5% to 7.5% in an attempt to boost in pharmaceutical manufacturing and the Make in India campaign.

Livestock animal segment accounted for the largest market share in terms of revenue in 2018, owing to increasing incidence of chronic diseases, awareness amongst animal healthcare organisations, and high animal healthcare spending in developing countries. It is difficult to assess pain in livestock animals and the visible symptoms are lameness, increased respiratory rate and increased vocalisation, expiatory grunt, and teeth grinding. The most commonly used medication are NSAIDS, ?2 adrenergic drugs, and local aesthetics.

Key players focus on implementing new strategies such as regional expansions, mergers and acquisitions, new product launch, R&D investments, partnerships, and distribution agreements to increase their revenue share. The major players profiled in this report include: Boehringer Ingelheim, Merck & Co, Zoetis, Elanco, Bayer Pharma AG, Ceva Sante Animale, Norbrook Laboratories, Baxter, Halyard, Bostonscientific, Lilly, Endo International, Forest Laboratories, Medtronic

Else, Place an Inquire before Purchase:

Customisation of the Report
In case of any queries or customisation requirements please connect with our sales team, who will ensure that your requirements are met.